Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Breed’s Hill Capital LLC more than tripled its stake in Eli Lilly during Q4, gobbling up 1,426 shares and pushing the company ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

Eli Lilly (NYSE:LLY) has received regulatory approval to market its Alzheimer’s therapy Kisunla (donanemab) in Australia, ...

Article originally published by. FE fundinfo is not responsible for its content or accuracy and may not share the author’s views. News and research are not personal recommendations to deal. All ...

Investing.com-- French pharmaceutical giant Sanofi SA (EPA:SASY) said on Wednesday it had entered an agreement to buy U.S.-listed biotech firm Vigil Neuroscience Inc (NASDAQ:VIGL), with focus chiefly ...

The separation is also expected to allow Medtronic to retire outstanding shares without impacting cash, leading to further ...

Broadcom managed to stay in the spotlight even as tech stocks tripped over a Q1 slump. ClearBridge Large Cap Value Strategy ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...

Eli Lilly (NYSE: LLY) is encouraged by trial data for its latest weight-loss and diabetes medications. Where to invest $1,000 ...

Major pharmaceutical manufacturing company Eli Lilly is considering a $5.7 billion investment into a facility in Houston.